Enhancing the Effect of PD-1/L1 Blockers by Polarizing M2 Tumor-associated Macrophages (TAMs)

Xinyan Zhang

doi:10.62051/7y98sy83

Authors

Xinyan Zhang

DOI:

https://doi.org/10.62051/7y98sy83

Keywords:

Tumor-associated macrophages (TAMs); PD-1/PD-L1; Tumor micro-environment (TME); Macrophage polarization; PD-1/L1 blockers.

Abstract

The cancerous microcosm, known as the tumor micro-environment (TME), encompasses a highly intricate network where a multitude of cells and their emitted substances significantly contribute to the development and advancement of malignant growths. The role of TAMs in the TME has been increasingly valued. Owing to its significant plasticity, it typically divides into pro-inflammatory M1 and anti-inflammatory M2. Within TME, TAMs typically show polarization towards M2. Antibodies are used by PD-1/L1 blockers to prevent PD-1 and PD-L1 from binding, aiming to reduce tumor symptoms. Presently, the efficacy of this medication is limited to a select few patients, in contrast to other patients who exhibit a level of resistance to the drug. Latest research indicates that M2 TAMs exert a suppressive influence on the PD-1/L1 blockade treatment. This substance suppresses the growth and penetration of CD8+T cells and generates Indole 2,3-dioxygenase (IDO), resulting in resistance to PD-1/L1 inhibitors and facilitating the multiplication and evasion of cancer cells. Some studies have reduced the resistance to PD-1/L1 blockers and promoted the treatment of tumors by polarizing TAMs. The dissertation compiles identified TAMs polarization routes and the impact of M2 TAMs on PD-1/L1 inhibitors. The discussion also encompasses present-day techniques for directing M2 TAMs towards the M1 type and advocating these approaches on PD-1/L1 blockers.

Downloads

Download data is not yet available.

References

[1] Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol, 2008, 66(1): 1-9.

[2] Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A, Di W. A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J Ovarian Res, 2014, 7: 19.

[3] Liliang Xia, Yuanyong Liu, Ying Wang. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. The Oncologist, 2019, 24(s1): S31-S41.

[4] Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med, 2018, 24: 1449-1458.

[5] Leisha A. Emens. Breast Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res, 2018, 24(3): 511-520.

[6] Baxi S, Yang A, Gennarelli RL, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ, 2018, 360: k793.

[7] Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med, 2015, 373(2): 123-135.

[8] Dhupkar P, Gordon N, Stewart J, Kleinerman ES. Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. Cancer Med, 2018, 7(6): 2654-2664.

[9] Munn DH, Mellor AL. IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol, 2016, 37(3): 193-207.

[10] van de Laar L, Saelens W, De Prijck S, et al. Yolk Sac Macrophages, Fetal Liver, and Adult Monocytes Can Colonize an Empty Niche and Develop into Functional Tissue-Resident Macrophages. Immunity, 2016, 44(4): 755-768.

[11] Murdoch C, Muthana M, Lewis CE. Hypoxia regulates macrophage functions in inflammation. J Immunol, 2005, 175(10): 6257-6263.

[12] Murray PJ. Macrophage Polarization. Annu Rev Physiol, 2017, 79: 541-566.

[13] Liu Y, Yan W, Tohme S, et al. Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. J Hepatol, 2015, 63(1): 114-121.

[14] Gebhardt C, Riehl A, Durchdewald M, et al. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med, 2008, 205(2): 275-285.

[15] Huber R, Meier B, Otsuka A, et al. Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages. Sci Rep, 2016, 6: 29914.

[16] Jiang M, Li X, Zhang J, et al. Dual Inhibition of Endoplasmic Reticulum Stress and Oxidation Stress Manipulates the Polarization of Macrophages under Hypoxia to Sensitize Immunotherapy. ACS Nano, 2021, 15(9): 14522-14534.

[17] Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med, 2011, 364(26): 2517-2526.

[18] O'Donnell JS, Smyth MJ, Teng MW. Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade? Genome Med, 2016, 8(1): 111.

[19] Mikucki ME, Fisher DT, Matsuzaki J, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun, 2015, 6: 7458.

[20] Peranzoni E, Lemoine J, Vimeux L, et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci U S A, 2018, 115(17): E4041-E4050.

[21] Gordon-Alonso M, Hirsch T, Wildmann C, van der Bruggen P. Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration. Nat Commun, 2017, 8(1): 793.

[22] Yuan Y, Adam A, Zhao C, Chen H. Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy. Cancers (Basel), 2021, 13(4): 663.

[23] Xiong H, Mittman S, Rodriguez R, et al. Anti–PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment. Cancer Res, 2019, 79(7): 1493-1506.

[24] Hsu SPC, Chen YC, Chiang HC, et al. Rapamycin and hydroxychloroquine combination alters macrophage polarization and sensitizes glioblastoma to immune checkpoint inhibitors. J Neurooncol, 2020, 146(3): 417-426.

[25] Wang YN, Wang YY, Wang J, et al. Vinblastine resets tumor-associated macrophages toward M1 phenotype and promotes antitumor immune response. J Immunother Cancer, 2023, 11(8): e007253.

[26] Guo T, Yang Y, Gao M, et al. Lepidium meyenii Walpers polysaccharide and its cationic derivative re-educate tumor-associated macrophages for synergistic tumor immunotherapy. Carbohydr Polym, 2020, 250: 116904.

[27] Ou DL, Chen CW, Hsu CL, et al. Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages. J Immunother Cancer, 2021, 9(3): e001657.

[28] Li Y, Shen Z, Chai Z, et al. Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity. Gut, 2023, 72(12): 2307-2320.

[29] Tang B, Zhu J, Wang Y, et al. Targeted xCT-mediated Ferroptosis and Protumoral Polarization of Macrophages Is Effective against HCC and Enhances the Efficacy of the Anti-PD-1/L1 Response. Adv Sci (Weinh), 2023, 10(2): e2203973.

[30] Rodell CB, Arlauckas SP, Cuccarese MF, et al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat Biomed Eng, 2018, 2(8): 578-588.

[31] Wei Z, Zhang X, Yong T, et al. Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles. Nat Commun, 2021, 12(1): 440.

[32] Yeung T, Ozdamar B, Paroutis P, Grinstein S. Lipid metabolism and dynamics during phagocytosis. Curr Opin Cell Biol, 2006, 18(4): 429-437.

[33] Van den Bossche J, O'Neill LA, Menon D. Macrophage Immunometabolism: Where Are We (Going)? Trends Immunol, 2017, 38(6): 395-406.

[34] Shan M, Qin J, Jin F, et al. Autophagy suppresses isoprenaline-induced M2 macrophage polarization via the ROS/ERK and mTOR signaling pathway. Free Radic Biol Med, 2017, 110: 432-443.

[35] Cao X, Li B, Chen J, et al. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer. J Immunother Cancer, 2021, 9(3): e002022.

[36] Ji X, Qian J, Rahman SMJ, et al. xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression. Oncogene, 2018, 37(36): 5007-5019.

[37] Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell, 2021, 12(8): 599-620.

[38] Wen ZF, Liu H, Gao R, et al. Tumor-secreted exosomes promote tumor self-seeding in a CD47-dependent manner. Cell Rep, 2021, 34(2): 108675.

[39] Savage P, Horton V, Moore J, Owens M, Witt P, Gore ME. A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer. 1996 Nov;74(9):1482-6.